A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer Clinical Trial

Official title:
A Randomized, Double-blind, Controlled, Parallel-cohort Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Status Completed

Clinical Trial Summary

This is a randomized, double-blind, controlled, parallel-cohort Phase II clinical study, which is planned to enroll 220 subjects with advanced cervical cancer who have failed or cannot tolerate first-line or above platinum-based chemotherapy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04590599
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	December 8, 2020
Completion date	November 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01088347` - Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer	Phase 1/Phase 2
Recruiting	`NCT05068921` - A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy	Phase 1
Terminated	`NCT02853604` - Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer	Phase 3
Recruiting	`NCT04731038` - Combination Therapy for First Line Treatment of Advanced Cervical Cancer	Phase 1
Recruiting	`NCT04508686` - Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)	Phase 1
Completed	`NCT02888717` - Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers	N/A